Supplemental Online Content

Longenecker CT, Jones KA, Hileman CO, et al. Nurse-led strategy to improve blood pressure and cholesterol level among people with HIV: a randomized clinical trial. *JAMA Netw Open*. 2024;7(3):e2356445. doi:10.1001/jamanetworkopen.2023.56445

This supplemental material has been provided by the authors to give readers additional information about their work.

eFigure 1. Study Accrual



eTable 1. Characteristics of People with HIV Who Consented to Participate in EXTRA-CVD Compared to Those Who Declined Participation After an Initial Phone Screen

Variable	Consented to participate in EXTRA-CVD	Did not consent to participate in EXTRA-CVD	p-value
N	299[b]	106	
Demographics			
Age (years), Mean (SD)	57.3 (9.6)	53.4 (11.4)	.003
Age (years), Median (Q1, Q3)	59.0 (52.0, 64.0)	56.0 (45.0, 62.0)	.003
Gender			.29
Male	234 (78.3%)	80 (75.5%)	
Female	62 (20.7%)	23 (21.7%)	
Transgender Male/Transman/FTM	1 (0.3%)	0 (0.0%)	
Transgender Female/Transwoman/MTF	2 (0.7%)	1 (0.9%)	
Other gender	0 (0.0%)	1 (0.9%)	
Unreported	0 (0.0%)	1 (0.9%)	
Sex			.85
Female	62 (20.7%)	23 (21.7%)	
Male	232 (77.6%)	82 (77.4%)	
Unreported	5 (1.7%)	1 (0.9%)	
Hispanic or Latino ethnicity			.003
Non-Hispanic	281 (94.0%)	101 (95.3%)	
Hispanic/Latino	17 (5.7%)	1 (0.9%)	
Unreported	1 (0.3%)	4 (3.8%)	
Race			.04
African American/Black	181 (60.5%)	65 (61.3%)	
American Indian/Alaskan Native	0 (0.0%)	1 (0.9%)	
White	100 (33.4%)	35 (33.0%)	
Other race	9 (3.0%)	1 (0.9%)	
Multiracial	7 (2.3%)	0 (0.0%)	
Unknown	2 (0.7%)	4 (3.8%)	

[a] This table includes all patients who were deemed eligible for EXTRA-CVD following the medical record review and participant screening. Demographic information was collected at the participant screening, as approved by the IRB.

[b] As shown in Figure 1 of the manuscript, n=299 is two higher than the n=297 who were included in the final analysis. One participant withdrew after consent but prior to randomization; another participant withdrew after randomization but prior to the baseline visit.

eTable 2. Patient Blood Pressure and Cholesterol Values at Baseline, Overall and by Treatment Arm

Variable	Overall N=297	Intervention N=149	Control N=148
Blood Pressure			
Systolic blood pressure, Mean (SD)	135.0 (18.8)	135.9 (18.1)	134.0 (19.5)
Diastolic blood pressure, Mean (SD)	81.1 (12.1)	81.2 (12.2)	81.0 (12.0)
Cholesterol			
Total cholesterol, Mean (SD)	184.7 (46.1)	185.1 (45.3)	184.4 (46.9)
LDL, Mean (SD)	111.8 (39.6)	111.5 (38.6)	112.1 (40.6)
HDL, Mean (SD)	45.2 (14.5)	45.8 (14.7)	44.7 (14.3)
Non-HDL, Mean (SD)	139.9 (44.6)	139.5 (44.6)	140.3 (44.9)
Triglycerides, Median (Q1, Q3)[a]	121.0 (89.0, 184.0)	127.0 (95.0, 182.0)	112.0 (85.0, 191.0)

[a]Median (Q1, Q3) presented due to skewness of the data

eFigure 2. Stacked Bar Chart of Blood Pressure Values at Baseline, by Anti-Hypertensive Treatment Status



eTable 3. Model-Estimated Outcome Means and Standard Errors or Proportions by Study Arm and Time Point

Outcomes	Baseline		4 months		8 months		12 months	
	Intervention estimate Mean (SE)[a]	Control estimate Mean (SE)[a]	Intervention estimate Mean (SE)[a]	Control estimate Mean (SE)[a]	Intervention estimate Mean (SE)[a]	Control estimate Mean (SE)[a]	Intervention estimate Mean (SE)[a]	Control estimate Mean (SE)[a]
Primary outcome								
Systolic blood pressure, mm Hg	134.9 (1.0)	134.9 (1.0)	129.9 (1.5)	136.3 (1.5)	129.3 (1.6)	133.0 (1.4)	129.7 (1.5)	133.9 (1.4)
Secondary outcome								
Non-HDL cholesterol, mg/dL	139.9 (2.5)	139.9 (2.5)	127.4 (3.5)	135.7 (3.4)	120.9 (3.5)	131.9 (3.3)	114.7 (3.5)	132.1 (3.3)
Tertiary outcomes								
Hypertension treatment cascade[b]	**%**	**%**	**%**	**%**	**%**	**%**	**%**	**%**
Untreated	10.8%	10.8%	7.8%	9.9%	3.2%	7.7%	5.7%	11.6%
Treated	47.3%	47.3%	34.3%	45.7%	33.2%	45.3%	34.4%	48.6%
At treatment goal	42.0%	42.0%	57.9%	44.4%	63.6%	47.0%	59.9%	39.8%
Hypercholesterolemia treatment cascade[b]	**%**	**%**	**%**	**%**	**%**	**%**	**%**	**%**
Untreated	37.5%	37.5%	18.1%	27.5%	5.9%	16.3%	5.3%	27.1%
Treated	20.5%	20.5%	15.7%	18.0%	9.0%	16.3%	3.6%	14.1%
At treatment goal	42.0%	42.0%	66.3%	54.5%	85.1%	67.4%	91.1%	58.7%
Exploratory outcomes								
Total cholesterol, mg/dL	184.9 (2.6)	184.9 (2.6)	172.4 (3.6)	179.9 (3.5)	165.8 (3.6)	176.4 (3.4)	161.5 (3.6)	177.5 (3.4)
HDL cholesterol, mg/dL	45.4 (0.9)	45.4 (0.9)	45.2 (1.1)	44.3 (1.0)	45.1 (1.1)	43.5 (1.0)	46.4 (1.1)	45.6 (1.0)
LDL cholesterol, mg/dL	111.5 (3.7)	111.5 (3.7)	107.4 (5.9)	115.4 (5.7)	93.3 (6.0)	104.7 (5.5)	96.4 (5.9)	107.0 (5.6)
Triglycerides, mg/dL	165.7 (7.7)	165.7 (7.7)	152.6 (10.4)	163.7 (10.1)	136.6 (10.5)	169.2 (9.8)	133.6 (10.5)	161.6 (9.9)

[a]Unless noted otherwise

[b]Categorized into one of the three mutually exclusive categories: untreated (regardless of whether it has been diagnosed), appropriately managed (at least one prescribed medication for hypertension/hypercholesterolemia), or at treatment goal (<130 systolic blood pressure for hypertension and <130 or <100 mg/dL, depending on risk score, for hypercholesterolemia)

eTable 4. Testing Sex as a Moderator of the Intervention Effects on Outcomes by Including an Interaction Term Between Study Arm, Study Visit, and Sex, With Male Sex Compared to Female (Reference Group)

Outcomes	Intervention effect						
	Overall joint test	4 months		8 months		12 months	
	p	Beta (95% CI)	p	Beta (95% CI)	p	Beta (95% CI)	p
Primary outcome							
Systolic blood pressure, mm Hg	.06	11.8 (2.0, 21.6)	.02	9.6 (-0.1, 19.3)	.05	5.9 (-3.8, 15.5)	.23
Secondary outcome							
Non-HDL cholesterol, mg/dL	.70	-11.1 (-31.6, 9.4)	.29	0.1 (-20.1, 20.4)	.99	0.4 (-19.9, 20.7)	.97
Tertiary outcomes							
Hypertension treatment cascade	.81						
Treated		1.4 (0.1, 16.1)	.77	0.5 (0.0, 9.0)	.61	0.5 (0.0, 6.5)	.60
At treatment goal		0.4 (0.0, 4.8)	.49	0.3 (0.0, 4.6)	.35	0.8 (0.1, 9.2)	.85
Hypercholesterolemia treatment cascade	.80						
Treated		1.9 (0.1, 34.7)	.68	0.6 (0.0, 14.3)	.73	0.1 (0.0, 3.0)	.20
At treatment goal		4.2 (0.3, 61.5)	.30	1.2 (0.1, 18.2)	.90	0.5 (0.0, 6.7)	.56
Exploratory outcomes							
Total cholesterol, mg/dL	.58	-12.7 (-33.5, 8.2)	.23	2.5 (-18.1, 23.1)	.81	-4.8 (-25.4, 15.9)	.65
HDL cholesterol, mg/dL	.36	-2.5 (-8.1, 3.0)	.37	0.9 (-4.6, 6.4)	.75	-3.8 (-9.3, 1.7)	.18
LDL cholesterol, mg/dL	.93	-7.5 (-46.7, 31.7)	.71	5.6 (-33.2, 44.3)	.78	8.0 (-30.9, 46.9)	.69

Outcomes	Intervention effect							
	Overall joint test	4 months		8 months		12 months		
	p	Beta (95% CI)	p	Beta (95% CI)	p	Beta (95% CI)	p	
Triglycerides, mg/dL	.40	2.0 (-57.6, 61.5)	.95	-47.1 -106.0, 11.9)	.12	-7.7 (-66.7, 51.3)	.80	

Overall joint test tests whether there is an overall moderating effect by sex

eTable 5. Testing ASCVD Risk as a Moderator of the Intervention Effects on Outcomes by Including an Interaction Term Between Study Arm, Study Visit, and ASCVD Risk, With High ASCVD Risk Compared to Low/Moderate Risk (Reference Group)

Outcomes	Intervention effect						
	Overall joint test	4 months		8 months		12 months	
	p	Beta (95% CI)	p	Beta (95% CI)	p	Beta (95% CI)	p
Primary outcome							
Systolic blood pressure, mm Hg	.24	-6.3 (-14.9, 2.3)	.15	-7.9 (-16.3, 0.6)	.07	-3.5 (-12.0, 5.0)	.42
Secondary outcome							
Non-HDL cholesterol, mg/dL	.53	5.1 (-12.5, 22.6)	.57	13.0 (-4.3, 30.4)	.14	5.5 (-12.0, 23.1)	.54
Tertiary outcomes							
Hypertension treatment cascade	.31						
Treated		1.8 (0.1, 24.0)	.65	0.8 (0.0, 17.5)	.89	0.3 (0.0, 3.6)	.33
At treatment goal		4.2 (0.3, 51.2)	.26	2.2 (0.1, 44.0)	.61	2.5 (0.2, 29.2)	.47
Hypercholesterolemia treatment cascade	.30						
Treated		11.4 (0.9, 147.7)	.06	6.2 (0.4, 99.2)	.20	3.1 (0.2, 62.3)	.45
At treatment goal		1.7 (0.2, 17.7)	.65	2.9 (0.2, 36.0)	.40	6.4 (0.5, 91.1)	.17
Exploratory outcomes							
Total cholesterol, mg/dL	.66	2.8 (-15.1, 20.7)	.76	11.3 (-6.5, 29.0)	.21	4.4 (-13.5, 22.3)	.63
HDL cholesterol, mg/dL	.46	-1.7 (-6.5, 3.2)	.50	-2.6 (-7.4, 2.2)	.30	-3.8 (-8.6, 1.0)	.12
LDL cholesterol, mg/dL	.12	38.9 (4.5, 73.4)	.03	12.9 (-21.0, 46.8)	.46	-9.6 (-44.1, 25.0)	.59

Outcomes	Intervention effect							
	Overall joint test	4 months		8 months		12 months		
	p	Beta (95% CI)	p	Beta (95% CI)	p	Beta (95% CI)	p	
Triglycerides, mg/dL	.63	13.0 (-34.3, 60.3)	.59	13.1 (-33.8, 59.9)	.58	31.7 (-15.5, 79.0)	.19	

Overall joint test tests whether there is an overall moderating effect by ASCVD risk

eTable 6. Testing Site as a Moderator of the Intervention Effects on Outcomes by Including an Interaction Term Between Study Arm, Study Visit, and Site, With Sites 2 and 3 Compared to Site 1 (Reference Group)

Outcomes	Intervention effect						
	Overall joint test	4 months		8 months		12 months	
	p	Beta (95% CI)	p	Beta (95% CI)	p	Beta (95% CI)	p
Primary outcome							
Systolic blood pressure, mm Hg	.70		.57		.80		.42
SBP, Site B		2.8 (-6.7, 12.3)	.57	-2.6 (-12.1, 7.0)	.59	-4.6 (-14.1, 4.9)	.34
SBP, Site C		-2.7 (-12.6, 7.3)	.60	0.5 (-9.3, 10.2)	.92	-6.3 (-16.2, 3.6)	.21
Secondary outcome							
Non-HDL cholesterol, mg/dL	.82		.93		.93		.39
Non-HDL, Site B		1.0 (-18.8, 20.8)	.92	-3.0 (-23.0, 16.9)	.77	13.9 (-6.0, 33.8)	.17
Non-HDL, Site C		3.9 (-17.0, 24.8)	.72	-3.5 (-23.9, 17.0)	.74	7.4 (-13.3, 28.1)	.48
Tertiary outcomes							
Hypertension treatment cascade	.91		.84		.53		.74
Treated, Site B		Not est.	.94	0.8 (0.0, 30.5)	.90	Not est.	.98
Treated, Site C		Not est.	.94	0.5 (0.0, 12.5)	.64	Not est.	.98
At treatment goal, Site B		Not est.	.93	3.9 (0.1, 138.9)	.45	Not est.	.99
At treatment goal, Site C		Not est.	.94	1.3 (0.1, 32.5)	.86	Not est.	.98

Outcomes	Intervention effect						
	Overall joint test	4 months		8 months		12 months	
	p	Beta (95% CI)	p	Beta (95% CI)	p	Beta (95% CI)	p
Hypercholesterolemia treatment cascade	.12		.95		.91		.01
Treated, Site B		0.9 (0.0, 21.4)	.92	1.3 (0.0, 43.0)	.88	61.3 (1.5, 2423.9)	.03
Treated, Site C		2.8 (0.1, 69.3)	.54	0.3 (0.0, 11.5)	.52	0.6 (0.0, 23.1)	.76
At treatment goal, Site B		1.3 (0.1, 22.7)	.86	1.7 (0.1, 41.1)	.75	0.5 (0.0, 11.0)	.64
At treatment goal, Site C		2.1 (0.1, 39.5)	.62	0.6 (0.0, 14.6)	.77	0.2 (0.0, 4.3)	.33
Exploratory outcomes							
Total cholesterol, mg/dL	.98		.98		.93		.74
Total cholesterol, Site B		-1.5 (-21.7, 18.7)	.88	-3.5 (-23.9, 16.8)	.73	7.3 (-13.0, 27.6)	.48
Total cholesterol, Site C		0.2 (-21.0, 21.5)	.98	-3.1 (-23.9, 17.7)	.77	6.6 (-14.4, 27.7)	.54
HDL cholesterol, mg/dL	**.02**		.41		.84		.009
HDL, Site B		-2.9 (-8.2, 2.5)	.29	1.5 (-3.9, 6.9)	.59	-8.0 (-13.3, -2.6)	.004
HDL, Site C		-3.5 (-9.1, 2.2)	.23	1.3 (-4.2, 6.8)	.64	-1.3 (-6.9, 4.3)	.64
LDL cholesterol, mg/dL	.67		.66		.90		.17
LDL, Site B		-1.6 (-38.9, 35.6)	.93	-2.6 (-40.4, 35.1)	.89	5.5 (-32.1, 43.0)	.78
LDL, Site C		16.1 (-24.3, 56.4)	.44	6.5 (-32.6, 45.6)	.74	36.1 (-3.8, 76.0)	.08
Triglycerides, mg/dL	.41		.29		.47		.89
Triglycerides, Site B		-7.1 (-64.7, 50.6)	.81	-32.2 (-90.5, 26.0)	.28	14.1 (-43.9, 72.1)	.63

Outcomes	Overall joint test	Intervention effect					
		4 months		8 months		12 months	
	p	Beta (95% CI)	p	Beta (95% CI)	p	Beta (95% CI)	p
Triglycerides, Site C		39.8 (-21.0, 100.7)	.20	-31.0 (-90.6, 28.5)	.31	8.1 (-52.1, 68.4)	.79

Overall joint test tests whether there is an overall moderating effect by site. Not est. = not estimable, valid estimates not available in some of the multinomial regression models

eTable 7. Intervention Effects Stratified by Treating Physician (EXTRA-CVD Investigator or Not)

Outcomes	Intervention effects											
	4 months				8 months				12 months			
	Study clinician		None		Study clinician		None		Study clinician		None	
	Beta (95% CI)	*p*	Beta (95% CI)	*p*	Beta (95% CI)	*p*	Beta (95% CI)	*p*	Beta (95% CI)	*p*	Beta (95% CI)	*p*
Primary outcome												
Systolic blood pressure, mm Hg	-7.3 (-15.8, 1.2)	.09	**-5.6 (-10.1, -1.2)**	**.01**	**-10.3 (-18.6, -2.0)**	**.01**	-1.0 (-5.4, 3.5)	.67	3.6 (-4.7, 11.8)	.39	**-6.3 (-10.7, -1.9)**	**.006**
Secondary outcome												
Non-HDL cholesterol, mg/dL	-14.9 (-33.5, 3.6)	.11	-5.7 (-15.0, 3.6)	.23	-12.2 (-30.4, 5.9)	.19	**-10.3 (-19.5, -1.0)**	**.03**	-14.6 (-32.7, 3.5)	.11	**-17.6 (-26.9, -8.4)**	**< .001**
Tertiary outcomes												
Hypertension treatment cascade	OR (95% CI)	*p*	OR (95% CI)	*p*	OR (95% CI)	*p*	OR (95% CI)	*p*	OR (95% CI)	*p*	OR (95% CI)	*p*
Treated	Not est.	**< .001**	0.5 (0.1, 1.7)	.27	Not est.	.82	1.4 (0.4, 5.8)	.61	Not est.	< .001	1.1 (0.3, 3.6)	.90
At treatment goal	Not est.	**< .001**	1.2 (0.4, 3.7)	.76	Not est.	.81	2.0 (0.5, 7.5)	.31	Not est.	< .001	2.5 (0.8, 8.0)	.12
Hypercholesterolemia treatment cascade	OR (95% CI)	*p*	OR (95% CI)	*p*	OR (95% CI)	*p*	OR (95% CI)	*p*	OR (95% CI)	*p*	OR (95% CI)	*p*
Treated	0.7 (0.1, 9.6)	.79	1.5 (0.4, 6.6)	.57	1.9 (0.1, 27.1)	.65	1.4 (0.3, 7.1)	.67	1.3 (0.1, 21.1)	.85	1.1 (0.2, 5.9)	.91
At treatment goal	1.4 (0.1, 19.4)	.79	1.7 (0.5, 5.5)	.41	15.2 (1.0, 233.3)	.05	2.0 (0.5, 7.5)	.31	7.7 (0.5, 116.6)	.14	**6.9 (1.9, 25.7)**	**.004**
Exploratory outcomes												

Outcomes	Intervention effects											
	4 months				8 months				12 months			
	Study clinician		None		Study clinician		None		Study clinician		None	
	Beta (95% CI)	*p*	Beta (95% CI)	*p*	Beta (95% CI)	*p*	Beta (95% CI)	*p*	Beta (95% CI)	*p*	Beta (95% CI)	*p*
Total cholesterol, mg/dL	-10.3 (-29.7, 9.1)	.30	-6.2 (-15.6, 3.1)	.19	-9.5 (-28.5, 9.5)	.32	**-10.4 (-19.7, -1.1)**	**.03**	-11.4 (-30.4, 7.5)	.24	**-16.7 (-26.1, -7.4)**	**< .001**
HDL cholesterol, mg/dL	3.3 (-0.9, 7.5)	.12	0.1 (-2.6, 2.8)	.93	1.5 (-2.6, 5.6)	.47	1.9 (-0.8, 4.5)	.17	2.3 (-1.8, 6.5)	.26	0.4 (-2.3, 3.1)	.77
LDL cholesterol, mg/dL	-12.4 (-28.6, 3.8)	.13	-1.1 (-21.5, 19.3)	.91	-7.0 (-23.1, 9.0)	.39	-7.1 (-27.3, 13.0)	.49	-9.8 (-25.7, 6.1)	.23	-4.3 (-24.7, 16.1)	.68
Triglycerides, mg/dL	-15.3 (-71.0, 40.4)	.59	-9.9 (-36.7, 17.0)	.47	-49.0 -103.7, 5.7)	.08	**-28.8 (-55.4, -2.1)**	**.03**	-22.1 (-76.8, 32.6)	.43	**-30.5 (-57.3, -3.7)**	**.03**

Not est. = not estimable, valid estimates not available in some of the multinomial regression models

eTable 8. Adverse Events by Treatment Arm

Variable	EXTRA-CVD Intervention	Education Control
N, total number of participants	149	148
Total participants with ≥1 AE	60 (40.3%)	55 (37.2%)
Number of AE per participant, among all participants		
Mean (SD)	0.7 (1.2)	0.8 (1.6)
Median (Q1, Q3)	0 (0, 1)	0 (0, 1)
Number of AE per participant, among those with ≥1 AE		
Mean (SD)	1.8 (1.2)	2.3 (1.9)
Median (Q1, Q3)	1 (1, 2)	2 (1, 3)
N, total number of adverse events	107	125
Serious AE	47 (43.9%)	47 (37.6%)
AE unexpected	39 (36.4%)	44 (35.2%)
AE grade		
Mild (Grade 1)	11 (10.3%)	12 (9.6%)
Moderate (Grade 2)	30 (28.0%)	44 (35.2%)
Severe (Grade 3)	56 (52.3%)	53 (42.4%)
Life-threatening (Grade 4)	8 (7.5%)	14 (11.2%)
Death (Grade 5)	2 (1.9%)	2 (1.6%)
AE related to study		
Not related	81 (75.7%)	96 (76.8%)
Unlikely to be related	22 (20.6%)	26 (20.8%)
Possibly related	1 (0.9%)	3 (2.4%)
Probably related	2 (1.9%)	0 (0.0%)
Definitely related	1 (0.9%)	0 (0.0%)

AE, adverse event

eTable 9. Sensitivity Analysis of Intervention Effects on Primary, Secondary, and Tertiary Outcomes, Adjusted for Baseline Covariates Associated With Attrition[a]

	Intervention effect					
Outcomes	**4 months**		**8 months**		**12 months**	
Primary outcome	Beta (95% CI)	*p*	Beta (95% CI)	*p*	Beta (95% CI)	*p*
Systolic blood pressure, mm Hg	**-5.7 (-9.7, -1.7)**	**.005**	-3.1 (-7.0, 0.9)	.13	-3.6 (-7.5, 0.4)	.08
Secondary outcome	Beta (95% CI)	*p*	Beta (95% CI)	*p*	Beta (95% CI)	*p*
Non-HDL cholesterol, mg/dL	**-8.7 (-17.1, -0.4)**	**.04**	**-11.2 (-19.5, -2.9)**	**.008**	**-17.6 (-25.9, -9.4)**	**< .001**
Tertiary outcomes	OR (95% CI)	*p*	OR (95% CI)	*p*	OR (95% CI)	*p*
Hypertension treatment cascade						
Treated	0.9 (0.3, 2.6)	.80	1.5 (0.4, 5.6)	.50	1.2 (0.4, 3.8)	.70
At treatment goal	1.3 (0.5, 3.7)	.61	2.6 (0.7, 8.9)	.14	2.4 (0.8, 6.9)	.12
Hypercholesterolemia treatment cascade						
Treated	1.4 (0.4, 4.8)	.55	1.6 (0.4, 5.8)	.51	1.3 (0.3, 5.2)	.68
At treatment goal	2.0 (0.7, 6.0)	.20	**3.8 (1.2, 12.2)**	**.03**	**8.8 (2.7, 28.2)**	**< .001**
Exploratory outcomes	Beta (95% CI)	*p*	Beta (95% CI)	*p*	Beta (95% CI)	*p*
Total cholesterol, mg/dL	-6.6 (-14.8, 1.5)	.11	**-9.4 (-17.5, -1.3)**	**.02**	**-15.2 (-23.4, -7.1)**	**< .001**
HDL cholesterol, mg/dL	1.1 (-1.2, 3.3)	.36	1.8 (-0.4, 4.1)	.11	1.0 (-1.2, 3.3)	.37
LDL cholesterol, mg/dL	-8.0 (-23.9, 7.8)	.32	-11.4 (-27.0, 4.1)	.15	-11.0 (-26.7, 4.7)	.17
Triglycerides, mg/dL	-12.4 (-36.5, 11.7)	.31	**-34.3 (-58.1, -10.5)**	**.005**	**-29.6 (-53.5, -5.7)**	**.02**

[a] Covariates associated with attrition were race, ethnicity, smoking status, mental health history, insurance status, and employment status. Sex was added as an additional covariate given the results of the moderation analyses. Covariates were tested for multicollinearity before entering into the final model